title: Pharmaceutical Approval Update.
abstract: Insulin degludec/liraglutide (Xultophy 100/3.6) for type-2 diabetes; rucaparib (Rubraca) for the treatment of deleteriousBRCAmutation-associated ovarian cancer; and nusinersen (Spinraza) for the treatment of spinal muscular atrophy.
authors.forename: Mary
authors.initials: M
authors.lastname: Choy